Evidence map›Paper›PMID 42361801›Full record

ArticleCell reports. Medicine2026

Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma.

Liangdong Sun, Jue Wang, Yilv Yan, Shengnan Duan, Di Wang, Jiameng Hu, Huansha Yu, Ningrui Wang, Min Zhang, Run Zhang and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Liangdong SunDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Jue WangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Yilv YanDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Shengnan DuanSchool of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
Di WangTissue Bank, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Jiameng HuSchool of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
Huansha YuDepartment of Animal Experimental Center, Innovation and Incubation Center, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Ningrui WangCentral Laboratory, Innovation and Incubation Center, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China; School of Laboratory Medicine, Nanchang Medical College, Nanchang, Jiangxi 330052, China.
Min ZhangSchool of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
Run ZhangSchool of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
Likun HouDepartment of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University Shanghai, Shanghai 200433, China.
Junjie HuDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Xinsheng ZhuDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Dongliang BianDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Shiqi HuDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Tao GeDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Yan ChenDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Lu HanDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Jinyi SongSchool of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
Ming DingSchool of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China. Electronic address: mingding@cpu.edu.cn.
Peng ZhangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China. Electronic address: zhangpeng1121@tongji.edu.cn.
Lele ZhangCentral Laboratory, Innovation and Incubation Center, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China. Electronic address: zhanglele@tongji.edu.cn.
Haiyang HuCentral Laboratory, Innovation and Incubation Center, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China. Electronic address: haiyanghu@cpu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary sarcomatoid carcinoma (PSC) is a rare yet highly invasive type of lung cancer that remains poorly characterized. Here, we conduct multi-omics analyses of PSC by integrating whole-exome sequencing, transcriptomic, proteomic, and phosphoproteomic data from 86 PSC patients, alongside single-cell RNA sequencing (scRNA-seq) data from 3 patients receiving neoadjuvant chemoimmunotherapy. We find an elevated ferroptosis suppression signature in PSC tumors and demonstrate their vulnerability to ferroptosis by targeting FTL and SLC3A2. Immune landscape characterization reveals an association between cold tumors, pleomorphic carcinoma, and PTEN mutations. Proteomic profiling identifies three distinct patient subtypes, each exhibiting unique features regarding microenvironment dysregulation, genetic alterations, and potential therapeutic targets. scRNA-seq analysis suggests roles of epithelial-mesenchymal transition in the progression from carcinoma cells to sarcomatoid cells and in immunotherapy resistance in PSC. Altogether, this multi-omics characterization of PSC serves as a rich resource for investigating mechanistic insights and identifying potential therapeutic targets.

Indexed as

Lung NeoplasmsEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMaleMultiomicsProteomicsTranscriptomeepithelial-mesenchymal transitionimmunotherapyproteogenomicpulmonary sarcomatoid carcinomascRNA-seq

Identifiers

PMID42361801
PMCPMC13400193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.